TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Intra-articular Injection of PRP Versus Corticosteriods in Treatment of Lumbar Facet Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Continuous or intermittent gradually progressive back pain for more than 3 months not significantly improving on medical treatment and/or physical modalities.~  * Patients age between 20 and 40 years.~ * Local / paraspinal pain or tenderness with or without radiation to buttock , groin or thigh.~ * Increase of pain on extension , rotation or lateral bending .~ * MRI detected synovitis of the facet joint as defined and graded by Czervionke and Fenton, 2008.~Exclusion Criteria:~* • Acute low back trauma, fractures, malignancies and inflammatory diseases.~  * Pain score of \< 4 at rest on visual analog scale.~ * Radicular neurologic complaints.~ * X-ray findings of long standing facet joint disease as; marked joint space narrowing, subchondral sclerosis or bone deformity/ sponylolithesis.~ * Evident disc herniation by MRI.~ * Prior surgery on the spine.~ * Prior interventional treatment on lumbar facet joints~ * Known hypersenstivity to local anesthesia, corticosteroid, contrast medium or blood derivatives.~ * Local or systemic infection or spinal infection.~ * Uncorrectable coagulopathy~ * Diabetes Mellitus~ * Pregnancy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Group (I) Platelet Rich Plasma (Type: ACTIVE_COMPARATOR): The participants are randomly assigned for intra-articular injection with autologous platelet rich plasma . The treated segments are determined by clinical signs and MRI detected facet joint synovitis .
- Group (II) Corticosteroids (Type: ACTIVE_COMPARATOR): The participants are randomly assigned for intra-articular injection with corticosteroids(a mixture of 0.5% lidocaine and 5mg/ml of betamethasone) . The treated segments will be determined by clinical signs and MRI detected facet joint synovitis .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 13-21 years~* Regular Marijuana smoker meeting DSM-IV criteria for cannabis dependence and seeking marijuana cessation treatment~Exclusion Criteria:~* Allergy or intolerance to NAC~* Pregnancy or lactation~* Use of carbamazepine or nitroglycerine (or any other drug deemed to be hazardous if taken with NAC) within 14 days of study participation~* Current enrollment in treatment for cannabis dependence~* Current substance dependence, other than cannabis or nicotine~* Significant medical or psychiatric illness that may place the participant at increased risk in the judgement of the study physician

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetylcysteine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* B-CLL~* Matutes score 4 or 5~* Binet stages B or C~* Age \> 65 years old~* No previous treatment of CLL by chemotherapy, radiotherapy or immunotherapy, except glucocorticoids \< 1 month~* Patient's written informed consent~* Life expectancy \> 6 months~Exclusion criteria~* Binet stage A~* ECOG performance status 2 or more~* Presence of a 17p deletion by FISH (\> 10% positive cores)~* Clinically significant auto-immune cytopenia, Coombs-positive hemolytic anemia as judged by the treating physician~* Patients with a history of another malignancy in complete remission less than 5 years, except basal cell skin cancer or tumor treated curatively by surgery~* Concomitant disease requiring prolonged use of corticosteroids (\> 1 month)~* Any severe co-morbidities such as NYHA Class III or IV heart failure, myocardial infarction within 6 months, unstable angina, ventricular tachyarrhythmias requiring ongoing treatment, severe uncontrolled myocardiopathy, uncontrolled hypertension, severe chronic obstructive pulmonary disease with hypoxemia, or uncontrolled diabetes mellitus.~* CIRS (Cumulative Illness rating Scale) \> 6~* Known hypersensitivity to murine proteins or to any of the study drugs or to their components~* Transformation into an aggressive B-cell malignancy (e.g. diffuse large cell lymphoma, Hodgkin lymphoma) or prolymphocytic leukemia~* Active bacterial, viral or fungal infection~* Seropositivity HIV, hepatitis C or hepatitis B (unless clearly due to vaccination)~* Total bilirubin, alkaline phosphatases and aminotransferases \> 2 x ULN~* Creatinine clearance \< 60 ml/min calculated according to the formula of Cockcroft and Gault~* Any coexisting medical or psychological condition that would preclude participation to the required study procedures~* Patient with mental deficiency preventing proper understanding of the requirements of treatment~Inclusion criteria at randomization~* Patients having received the full induction phase with 4 FC and 6 rituximab courses (with/without dose adjustments as per protocol)~* Complete or partial response according to NCI and iwCLL criteria at the end of induction phase~* Recovery from FCR toxicities~* Patient willingness to continue on protocol

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observation (Type: NO_INTERVENTION): Observation every 8 weeks during 2 years
- rituximab arm (Type: EXPERIMENTAL): rituximab :500 mg/m² every 8 weeks during 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* LDL-C \> 70 mg/dL and TG \< 400 mg/dL,~* Treated with a high-intensity statin therapy~Exclusion Criteria:~* BMI \> 40 kg/m~* Significant cardiovascular disease~* HbA1c \> 10%~* Uncontrolled hypertension~* Active muscle disease~* GFR \< 60 ml/min~* Hepatic dysfunction~* Anemia~* History of malignancy~* Alcohol abuse~* Treatment with investigational product~* Treatment with PCSK9~* Clinically significant condition~* Known CETP inhibitor allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): once-daily placebo
- obicetrapib 5 mg (Type: EXPERIMENTAL): once-daily obicetrapib
- obicetrapib 10 mg (Type: EXPERIMENTAL): once-daily obicetrapib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Overactive bladder syndrome~Exclusion Criteria:~* Less than 8 micturitions in 24 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 seropositive~* HSV-2 seropositive~* Plans to deliver in Nairobi~* Resides and plans to remain in Nairobi for 12 months postpartum~* 18 years of age or older~* CD4 count\>250 cells/μl~Exclusion Criteria:~* indication for highly active antiretroviral therapy (e.g., WHO stage III or IV)~* hypersensitivity to valacyclovir or acyclovir

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
- 2 (Type: PLACEBO_COMPARATOR): oral placebo twice daily from 34 weeks gestation to 1 year postpartum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comfort Talk and Economic Outcomes in MRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must routinely perform MRI examinations~* Must capture data on noncompletion of MRI scans~Exclusion Criteria:~* No dedicated MRI unit~* Unable to reliably capture data on noncompletion of MRI scans

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Comfort Talk® Training (Type: EXPERIMENTAL): In the experimental group, MRI personnel is trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests at the onset of the MRI scan.
- Control (Type: NO_INTERVENTION): MRI sites not trained in Comfort Talk®.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Kappa Agonist on Hot Flashes in Menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy women 45-60 years of age; 12 months amenorrhea~2. Documentation of \> 8 moderate to severe, daily hot flashes during one week of baseline monitoring using daily diaries~3. Availability of a family member or friend to drive participant home following clinic visits~Exclusion Criteria:~1. Use of hormonal prescription medication or supplements for vasomotor symptoms (VMS)~2. Use of narcotics~3. Use of SSRI (selective serotonin reuptake inhibitor)/SNRI (serotonin-norepinephrine reuptake inhibitors), gabapentin, MAOI (monoamine oxidase inhibitor), anti-epileptics, sedatives~4. History of polycystic ovarian syndrome or hirsutism~5. Current history of depression~6. Any chronic or acute medical illnesses including renal, hepatic, pulmonary diseases, or seizures~7. Substance abuse~8. Severe corn allergy~9. Known allergic reaction to pentazocine or naloxone~10. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data~11. Hysterectomy~12. Use of anticholinergic medications~13. Lactating or pregnant

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Cornstarch, National Formulary
- Standard Dose Kappa Agonist (Type: EXPERIMENTAL): Pentazocine/Naloxone 50/0.5 mg
- Half Dose Kappa Agonist (Type: EXPERIMENTAL): Pentazocine/Naloxone 25/0.25 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Intraoperative Clonidine for Prevention of Postoperative Agitation in Pedriatic Anesthesia With Sevoflurane.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 2 - 12 Years.~* Need for tonsillectomy / adenotonsillectomy.~* Physical status of the American Society of Anesthesiologists (ASA) 1, 2 or 3.~* Anestesia geral com sevoflurano.~* Use of Intraoperative dipyrone, 30-50mg/Kg, IV.~Exclusion Criteria:~* Changes in consciousness.~* Neurological Deficit.~* Use of another drug as medication before anesthesia.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Clonidine (Type: EXPERIMENTAL): Clonidine 1μg/Kg, IV, single dose, anesthesia intraoperative.
- No Clonidine (Type: NO_INTERVENTION): Usual care of Instituto de Medicina Integral Prof. Fernando Figueira.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thiamine Responsive Disorders (TRD) Among Infants in Lao PDR

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria of hospital-based children:~* 21 days to \<18 months and seeking care at the collaborating hospital and meeting at least one of the following inclusion criteria:~* Liver enlargement (\>2 cm below right costal margin on calm, supine exam)~* Edema~* Tachypnea (\> 60/min for 3-8 wks; \>50/min for 2-11 mo; \>40/min for 12 - 18 mo)~* Tachycardia (heart rate \>160/min for \<12 mo; \>120/min for 12 mo - 18 mo)~* Oxygen saturation (\<92%)~* Difficulty breathing (i.e. chest in-drawing, nasal flaring)~* Refusal to breastfeed or refusal of infant formula or food for greater than 24 hours~* Repetitive or recurring vomiting with no obvious other cause(i.e. vomiting \>3 times in past 24 hours)~* Persistent crying not relieved by soothing and feeding with no obvious other cause~* Hoarse voice/cry or loss of voice~* Nystagmus or other unusual eye movement~* Muscle twitching~* Loss of consciousness~* Convulsion~* Opisthotonus / abnormal posturing~* Acute paralysis / flaccid paralysis~Exclusion criteria of hospital-based children:~- None~Inclusion criteria of community-based children, who will be frequency-matched based on sex, age and residence to hospital-based participants :~* Children aged 21 days to \<18 months~* Residing in selected communities~Exclusion criteria of community-based children:~- Severe acute illness warranting immediate hospital referral~Inclusion criteria of participants' mothers:~- Mother of hospital-based study participant or community-based study participant~Exclusion criteria of participants' mothers:~* Severe acute illness warranting immediate hospital referral~* Unable to provide informed consent due to reduced decision making ability

- Gender: ALL
- Minimum Age: 21 Days
- Maximum Age: 17 Months
- Healthy Volunteers: t

Study Arms:
- Hospital-based cohort (Type: None): 100 mg thiamine provided via intramuscular and/or intravenous injection (Thiamine 100 MG/ML) daily for 3 days
- Community-based cohort (Type: None): Sex-, age- and regionally matched comparison group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of SCCHN~* Recurrent and/or metastatic SCCHN, not suitable for local-regional treatment~* Presence of at least 1 measurable lesion according to RECIST Version 1.1~* Signed written informed consent before any trial-related activities are carried out~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Other protocol-defined inclusion criteria could apply~Exclusion Criteria:~* Prior systemic chemotherapy, except if given as part of multimodal treatment for locally advanced disease, that was completed within 6 months before randomization~* Surgery (excluding prior biopsy for diagnosis) or irradiation within 4 weeks before trial entry~* Previous treatment with monoclonal antibody or signal transduction inhibitors targeting epidermal growth factor receptor~* Nasopharyngeal carcinoma~* Known central nervous system metastasis and/or leptomeningeal disease~* Medical or psychological condition that would not permit the participant to complete the trial or sign informed consent~* Legal incapacity or limited legal capacity~* Other protocol-defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (Type: EXPERIMENTAL): None
- Cisplatin/Carboplatin + 5-Flurouracil (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone After Liver Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* liver transplant~Exclusion Criteria:~* dual organ transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SOC-Standard of care (Type: NO_INTERVENTION): standard of care, nontreatment
- spironolactone (Type: EXPERIMENTAL): spironolactone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes (based on the World Health Organization \[WHO\] diagnostic criteria) for at least 1 year.~* Have diet and exercise therapy only (no oral antihyperglycemic medication for at least 3 months prior to screening).~* Have a fasting blood glucose value of ≥120 and ≤200 milligrams per deciliter (mg/dL) at screening.~* Have a screening body weight of ≥50 and ≤80 kilograms.~Exclusion Criteria:~* Have known allergies to dulaglutide, or other glucagon-like peptide-1 (GLP-1) receptor agonists.~* Have had a clinically significant cardiovascular disease.~* Have a known clinically significant gastric emptying abnormality or have undergone gastric bypass surgery or restrictive bariatric surgery.~* Have acute or chronic hepatitis, signs and symptoms of any other liver disease.~* Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis.~* Have an estimated glomerular filtration rate (eGFR) \<30 milliliters/minute/1.73 meter squared.~* In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dulaglutide, Placebo (Type: EXPERIMENTAL): Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
- Placebo, Dulaglutide (Type: EXPERIMENTAL): Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, ≥ 40 years of age at screening (inclusive)~2. Reported more than 7-8 moderate to severe hot flashes per day (average) or 50-60 moderate to severe hot flashes per week for at least 30 days prior to the screening visit~3. Spontaneous amenorrhea for at least 12 consecutive months or~4. Amenorrhea for at least 6 months and meet the biochemical criteria for menopause or~5. Bilateral salpingo-oophorectomy ≥ 6 weeks with or without hysterectomy~Exclusion Criteria:~1. Known non-responder to previous Selective serotonin reuptake inhibitor (SSRI) or Serotonin norepinephrine reuptake inhibitor (SNRI) treatment for VMS~2. History of self injurious behavior~3. History of clinical diagnosis of depression or treatment for depression~4. History of clinical diagnosis of borderline personality disorder~5. Use of an investigational study medication within 30 days prior to screening or during the study~6. Concurrent participation in another clinical trial or previous participation in this trial~7. Family of investigational-site staff

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brisdelle (paroxetine mesylate) (Type: EXPERIMENTAL): Brisdelle (paroxetine mesylate)
- Placebo Capsules (Type: PLACEBO_COMPARATOR): Placebo Capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete